chartexchange

Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire Inc. | Nov 5, 2026 6:47 AM EST

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027

Read original article